Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04984408
Other study ID # IVI-ECOVA-01
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date October 1, 2021
Est. completion date September 30, 2024

Study information

Verified date August 2021
Source International Vaccine Institute
Contact Florian Marks, PhD
Phone + 821087033813
Email fmarks@ivi.int
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To expand the access and delivery of COVID-19 Vaccines in Africa (ECOVA), the investigators will conduct a phase 3, individually randomized, observer-blind, controlled (influenza vaccine) trial to evaluate the safety and efficacy of the BBIBP-CorV vaccine against any severe acute respiratory syndrome 2 (SARS-CoV- 2) infection among adults 18 years and older. The BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by the Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China and received emergency use authorization (EUA) from World Health Organization (WHO).


Description:

The investigators will conduct a randomized, observer-blind, controlled, phase 3 trial will be conducted to assess the safety, immunogenicity and efficacy of two doses of intramuscular BBIBP-CorV vaccine, followed by a booster dose, in adults 18 years of age and older. . Study Arms 1 and 2 will have two groups: group 1 - HIV-uninfected receiving BBIBP-CorV or Flu Quadrivalent; group 2 - HIV-infected receiving BBIBP-CorV or Flu Quadrivalent. Arm 3 will have 1 group - HIV-uninfected co-administration group receiving both vaccines. The randomization will be stratified by HIV status. Active surveillance for covid-19 will be carried out and immunogenicity will be assessed for a subset of population.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 8825
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female and male adults aged 18 years and older (Arm 1-Group 1 and Arm 2-Group 1) and 18-65 years (Arm 1 - Group 2, Arm 2-Group 2 and Arm3-Group1) at the time of consent. - Residing within the Beira and Maputo health region and planning to stay for the study duration. - HIV-negative test result at the day of screening for participants in Group 1, in Arms 1, 2 and 3 - HIV-positive and on anti-retroviral treatment for at least six months for participants in Group 2, in Arms 1 and 2 - Female volunteers of childbearing potential with a negative pregnancy test on the day(s) of screening and vaccination, practicing/willing to practice continuous effective contraception recommended by the national health system up to four weeks after the third vaccination. - Able and willing to comply with all study requirements, based on the assessment of the investigator. - Provide written informed consent before any trial procedure. Exclusion Criteria: - Pregnant, lactating, or with intention to become pregnant during the study. - Planned receipt of any investigational vaccine than the study intervention within 28 days before and after each study vaccination. - Active COVID-19 infection at the time of enrollment - History of allergic reactions or anaphylaxis to previous immunization or allergies to any components of the vaccines. - History of bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venipuncture (for the immunogenicity subset and HIV infected participants). - Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial or result in incomplete or poor quality data.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China Dose formulation: A liquid formulation containing 4µg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose). Mode of Administration: Intramuscular Storage Conditions: 2 to 8 degree Celsius
influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent) Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults) Mode of Administration: Intramuscular Storage Conditions: 2 to 8 degree Celsius

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
International Vaccine Institute

Outcome

Type Measure Description Time frame Safety issue
Other Acute phase reactants in COVID-19 patients that best predict COVID-19 disease and, hence, the control of protection against COVID-19 infection. Acute phase reactants in COVID-19 patients that best predict COVID-19 disease and, hence, the control of protection against COVID-19 infection. Till two years follow up from the date of enrollment
Other Profile of the epitope-specific humoral immune response that tracks with protective immunity following natural infection or vaccine-induced immunity, using Systems Serology Profile of the epitope-specific humoral immune response that tracks with protective immunity following natural infection or vaccine-induced immunity, using Systems Serology Till two years follow up from the date of enrollment
Other Any pregnancy outcomes after immunization in the intervention arm(s) as compared to control arm(s). Any pregnancy outcomes after immunization in the intervention arm(s) as compared to control arm(s) Till two years follow up from the date of enrollment
Other The medical and psychological outcomes of COVID-19 patients in the first two years of follow-up The medical and psychological outcomes of COVID-19 patients in the first two years of follow-up Till two years follow up from the date of enrollment
Other Identify novel SARS-CoV-2 host targets and host-virus interactions in low- and middle-income countries (LMIC) participants. Identify novel SARS-CoV-2 host targets and host-virus interactions in low- and middle-income countries (LMIC) participants. Till two years follow up from the date of enrollment
Primary Protection conferred by BBIBP-CorV vaccine against any COVID-19 disease Protection conferred by BBIBP-CorV vaccine against any COVID-19 disease measured as the reduction in incidence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) confirmed COVID-19 disease in the BBIBP-CorV vaccine arm (s) compared to the control arm, 7 days after the second dose of study intervention Up to two years follow up from the date of enrollment
Secondary Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs) Incidence of local solicited adverse events within 7 days and systemic solicited adverse events within 14 days of each vaccination, unsolicited adverse events within 28 days of each vaccination, serious adverse events and adverse events of special interest (AESIs) throughout the duration of the study according to the Brighton collaboration list for COVID-19 vaccine studies local solicited adverse events within 7 days and systemic solicited adverse events within 14 days of each vaccination, unsolicited adverse events within 28 days of each vaccination
Secondary Protection conferred by BBIBP-CorV vaccine against symptomatic COVID-19 disease Protection conferred by BBIBP-CorV vaccine against symptomatic COVID-19 disease caused by variants of concerns (VoCs) measured as the reduction in incidence of RT-PCR-confirmed symptomatic COVID-19 disease caused by variants of concerns (VoCs) in the BBIBP-CorV vaccine arm (s) compared to the control arm, 7 days after the second dose of study intervention. Till two years follow up from the date of enrollment
Secondary Protection conferred by BBIBP-CorV vaccine against asymptomatic SARS-CoV-2 infection (any SARS-CoV-2 variant) Protection conferred by BBIBP-CorV vaccine against asymptomatic SARS-CoV-2 infection (any SARS-CoV-2 variant) measured as the reduction in incidence of RT-PCR-confirmed asymptomatic COVID-19 disease in the BBIBP-CorV vaccine arm (s) compared to the control arm 7 days after the second dose of study intervention. Till two years follow up from the date of enrollment
Secondary Protection conferred by BBIBP-CorV vaccine against severe COVID-19 disease and COVID-19 associated death Protection conferred by BBIBP-CorV vaccine against severe COVID-19 disease and COVID-19 associated death, measured as the reduction in incidence of RT-PCR-confirmed severe COVID-19 hospitalization and death in the BBIBP-CorV vaccine arm (s) compared to the control arm. Till two years follow up from the date of enrollment
Secondary Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants, at Visit 2 (Day 0) , Visit 4 (day 28) , Visit 6 (day 56), Visit 7 (day 112), Visit 9 (day 140) Visit 10 (day 280) and Visit 11 (day 700) Till two years follow up from the date of enrollment
Secondary Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs) in HIV-infected adults Incidence of local solicited adverse events within 7 days and systemic solicited adverse events within 14 days of each vaccination, unsolicited adverse events within 28 days of each vaccination, serious adverse events and adverse events of special interest (AESIs) according to Brighton Collaboration list for COVID-19 vaccine studies throughout the duration of the study in HIV-infected adults as compared to equal number of HIV-uninfected adults receiving the BBIBP-CorV vaccine and in HIV-infected adults receiving the control vaccine Till two years follow up from the date of enrollment
Secondary Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants in HIV-infected adults Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants, at Visit 2 (Day 0) , Visit 4 (day 28) , Visit 6 (day 56), Visit 7 (day 112), Visit 9 (day 140) Visit 10 (day 280) and Visit 11 (day700) in HIV-infected adults as compared to in HIV-uninfected adults receiving the BBIBP-CorV vaccine and in HIV-infected adults receiving the control vaccine Till two years follow up from the date of enrollment
Secondary SARS-CoV-2 sequence variants among HIV-infected and HIV-uninfected, BBIBP-CorV vaccine and placebo recipients SARS-CoV-2 sequence variants among HIV-infected and HIV-uninfected, BBIBP-CorV vaccine and placebo recipients Till two years follow up from the date of enrollment
Secondary Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in the Arm 3 as compared to Arm 1 and 2 (subset participants). Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in the Arm 3 as compared to Arm 1 and 2 (subset participants), at Visit 2 (Day 0) , Visit 4 (day 28) , Visit 6 (day 56), Visit 7 (day 112), Visit 9 (day 140) Visit 10 (day 280) and Visit 11 (day 700) Till two years follow up from the date of enrollment
Secondary Incidence of adverse event (AE) after each vaccination, serious adverse event (SAE), adverse events of special interests (AESIs) according to Brighton Collaboration list for COVID-19 vaccine studies among participants receiving the study vaccines. Incidence of adverse event (AE) after each vaccination, serious adverse event (SAE), adverse events of special interests (AESIs) according to Brighton Collaboration list for COVID-19 vaccine studies throughout the duration of the study. Till two years follow up from the date of enrollment
Secondary Humoral and cellular immune responses of HIV-infected participants as compared to HIV-uninfected vaccine and control arms (subset participants of Arms 1 and 2) Humoral and cellular immune responses of HIV-infected participants as compared to HIV-uninfected vaccine and control arms (subset participants of Arms 1 and 2) at Visit 2 (Day 0) , Visit 4 (day 28) , Visit 6 (day 56), Visit 7 (day 112), Visit 09 (day 140) Visit 10 (day 280) and Visit 11 (day 700). Till two years follow up from the date of enrollment
Secondary Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody following booster dose of BBIBP-CorV vaccine Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody at Visit 7 (day 112), Visit 09 (day 140) Visit 10 (day 280) and Visit 11 (day 700) following booster dose of BBIBP-CorV vaccine. Till two years follow up from the date of enrollment
Secondary Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs) among HIV uninfected adults. Incidence of local solicited adverse events within 7 days and systemic solicited adverse events within 14 days of booster dose, unsolicited adverse events within 28 days of booster dose and serious adverse events, and adverse events of special interest (AESIs) according to Brighton Collaboration list for COVID-19 vaccine studies throughout the duration of the study among HIV uninfected adults in the BBIBP-CorV vaccine arm (s) compared to the control arm. Till two years follow up from the date of enrollment
See also
  Status Clinical Trial Phase
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Recruiting NCT04587323 - VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Completed NCT04682873 - A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus Phase 3
Completed NCT04359212 - Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
Completed NCT05603130 - Epidemiologic Register on Diabetes and COVID-19 in Tunisia
Completed NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC Phase 1/Phase 2
Completed NCT04757792 - Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Active, not recruiting NCT04417257 - Study of LAU-7b for the Treatment of COVID-19 Disease in Adults Phase 2/Phase 3
Recruiting NCT04522037 - Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
Completed NCT04446377 - A Study of LAM-002A for the Prevention of Progression of COVID-19 Phase 2
Active, not recruiting NCT04969172 - A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection Phase 2
Completed NCT04347369 - A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
Completed NCT04366024 - A Novel Nomogram to Predict Severity of COVID-19
Completed NCT04787510 - COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Completed NCT05329220 - ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 Phase 3
Active, not recruiting NCT05077267 - ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects Phase 2
Completed NCT04472013 - Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
Active, not recruiting NCT04371354 - Outcomes of Covid-19 Protective Measures in Endoscopy
Not yet recruiting NCT04779359 - Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease

External Links